CDT Equity Inc
cdtequity.comWhat Do They Do?
Develops drug candidates and solid-form intellectual property, then seeks licensing partners among pharmaceutical and biotechnology companies.
10-K for FY2025, filed Apr 15, 2026CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., a Delaware corporation (“CDT”, “CDT Equity” or the “Company”), is a data-driven…View ↗
The Company’s strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger…View ↗
We believe that successful pre-clinical trials of the assets in our pipeline will increase the value of our assets. There is no assurance…View ↗
To enable us to monetize our clinical assets, we, in partnership with CROs and KOLs, intend to conduct additional pre-clinical trials on…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Apr 15, 2026
Who Are Their Customers?
The company expects to license drug assets to biotech and pharmaceutical companies after pre-clinical trials; those partners would take them through further development and commercialization.
10-K for FY2025, filed Apr 15, 2026We believe that successful pre-clinical trials of the assets in our pipeline will increase the value of our assets. There is no assurance…View ↗
To enable us to monetize our clinical assets, we, in partnership with CROs and KOLs, intend to conduct additional pre-clinical trials on…View ↗
We anticipate developing clinical assets, which we own or license from third parties, that have undergone pre-clinical and clinical trials…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$4.6MView ↗
- ▼ −23% (Loss)
- vs −$6M in Q2 FY2025
-
Sep 1, 2026
James Bligh became CEO as Andrew Regan resigned
Bligh will continue as CFO until a successor is named; Regan resigned from both the CEO role and the Board.
Sources
8-K, filed Sep 1, 2026
On August 31, 2026 (the “Effective Date”), CDT Equity Inc (the “Company”) appointed Mr. James Bligh to serve as Chief Executive Officer…View ↗
From acquisition search to drug development
The older report described a blank-check company seeking a business combination, with a focus on real estate and property technology. The latest describes a pharmaceutical development business advancing therapeutic assets and seeking licensing deals.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Apr 15, 2026
Loading...
